The Obesity Controversy: Does It Impact Treatment Response in Diffuse Large B-Cell Lymphoma?

Suheyla Atak; Istemi Serin; Naciye Demirel; Esma  Evrim Dogan; Demet Aydın; Nihan Nizam; Ilknur Mansuroglu; Rafet Eren

doi:10.18502/ijhoscr.v17i2.12643

Suheyla Atak University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Istemi Serin University of Health Sciences, Istanbul Training and Research Hospital, Department of Hematology, Istanbul, Turkey
Naciye Demirel University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Esma Evrim Dogan University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Demet Aydın University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Nihan Nizam University of Health Sciences, Çiğli Training and Research Hospital, Department of Internal Medicine, İzmir, Turkey
Ilknur Mansuroglu University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Rafet Eren Istinye University, Faculty of Medicine, Department of Hematology, Istanbul, Turkey

DOI: https://doi.org/10.18502/ijhoscr.v17i2.12643

Keywords: Diffuse large B-cell Lymphoma; Obesity; Body mass index

Abstract

Background: We aimed to investigate the association of body mass index (BMI) with treatment response in patients with DLBCL

Material and Methods: Seventy-nine DLBCL subjects were included in this study. Data about patient age, sex, serum LDH level, presence of B symptoms, IPI score, ECOG performance score, disease stage, extranodal involvement, and BMI values at diagnosis were retrieved by retrospective patient record review. Patients were staged according to Ann Arbor classification using CT and/or PET/CT findings, and the presence of B symptoms. Body mass index was calculated by dividing weight in kilograms by height in meters squared (kg/m²). Patients were divided into groups according to their BMI as underweight (BMI≤ 18.5 kg/m²), normal weight (BMI 18.5-25 kg/m²), overweight (BMI 25-30 kg/m²), and obese (BMI≥ 30 kg/m²), as defined by the World Health Organization.

Results: Patients were divided into four groups according to their BMIs, but because there was only one patient in the underweight group, comparisons were performed between normal-weight, overweight, and obese patients. There was no statistically significant difference between these groups in terms of age, sex, serum LDH level, disease stage, presence of B symptoms, extranodal involvement, ECOG performance score, IPI score and treatment response (p= 0.070, 0.704, 0.325, 0.464, 0.254, 0.152, 0.658, 0.620, and 0.947, respectively)

Conclusion: In our study, we showed that BMI has no significant impact on treatment response in patients with DLBCL.